The EU Portfolio remains narrowly focused and fully aligned with its mandate: owning European companies listed on major regional exchanges. As of this review, the portfolio holds two positions: Arcadis N.V., listed on Euronext Amsterdam, and SUSS MicroTec SE, listed on the Frankfurt Stock Exchange / Deutsche Börse Xetra. Both holdings are recent additions, both are currently profitable based on stored quote-history performance, and both remain inside the protected minimum holding period.
Current Positioning
This is still a concentrated two-stock portfolio. Arcadis provides exposure to European engineering, infrastructure, water, climate resilience, mobility, and built-environment consulting. SUSS MicroTec adds a very different driver: European semiconductor-equipment exposure tied to advanced backend processes, AI-chip-module demand, and broader semiconductor capital spending.
| Holding | Exchange Discipline | Pick Date | Stored Return | Action |
|---|---|---|---|---|
| Arcadis N.V. (ARCVF) | Euronext Amsterdam | 2026-06-06 | +8.66% | Hold |
| SUSS MicroTec SE (SESMF) | Frankfurt / Xetra | 2026-06-09 | +7.48% | Hold |
Performance Review
The portfolio has had a strong start. Arcadis is up 8.66% from its stored first quote, while SUSS MicroTec is up 7.48%. These are encouraging early moves, but they should not be overinterpreted. Both positions are newly opened, and the portfolio is still in the early thesis-validation stage rather than the harvesting stage.
Arcadis’ recent Q1 2026 update supports the holding case. The company reported order intake of approximately €1.1 billion, a 1.19x book-to-bill, backlog of about €3.8 billion, and an operating EBITA margin of 11.0%. Management highlighted strength in order intake and backlog, with growth supported by areas such as mobility, water, climate, advisory, and resilience, while also noting challenges in parts of Property & Investment, including Canada and China. ([arcadis.com](https://www.arcadis.com/en/news/global/2026/arcadis-q1-2026-trading-update?utm_source=openai))
SUSS MicroTec’s Q1 2026 update also supports the thesis, though with a more cyclical profile. The company reported record first-quarter order intake of €149.3 million, up 69.5% year over year, with an order book of €330.1 million at the end of March. Sales of €86.5 million were lower year over year, and the EBIT margin of 4.3% shows that revenue timing and cost absorption still matter. Management confirmed 2026 guidance for sales of €425 million to €485 million, gross margin of 35% to 37%, and EBIT margin of 8% to 10%. ([suss.com](https://www.suss.com/en/news/corporate-news/2026/order-intake-reaches-record-level-in-the-first-quarter-of-2026?utm_source=openai))
Portfolio Fit and Regional Discipline
There is no regional-fit issue this week. Arcadis is a Netherlands-based company listed on Euronext Amsterdam, while SUSS MicroTec is a Germany-based company listed on Frankfurt/Xetra. Both holdings fit the EU Portfolio’s regional and main-exchange discipline. The portfolio is not drifting into U.S. listings, OTC-only exposure, or non-European thematic substitutes.
Risk Concentration
The main risk is not position quality; it is concentration. With only two holdings, company-specific news can drive a large portion of weekly performance. The portfolio also has a growth and capital-spending tilt: Arcadis benefits from infrastructure and public/private project spending, while SUSS MicroTec is exposed to semiconductor equipment cycles and the timing of customer orders.
That said, the two holdings are not duplicates. Arcadis is more services-, infrastructure-, and resilience-oriented, while SUSS MicroTec is more technology-hardware and semiconductor-cycle exposed. This gives the portfolio some useful internal diversification, even though the number of holdings remains small.
What to Watch Next
- Arcadis: Watch whether backlog growth converts into stronger organic revenue growth, whether margins continue improving, and whether weakness in Property & Investment remains contained.
- Arcadis catalyst: The company has indicated that a Capital Markets Day is scheduled for September 29, 2026, which could reset medium-term targets and clarify strategic priorities. ([arcadis.com](https://www.arcadis.com/en/news/global/2026/arcadis-q1-2026-trading-update?utm_source=openai))
- SUSS MicroTec: Watch whether record order intake converts into second-half revenue, whether gross margin stays inside the 35% to 37% guidance range, and whether EBIT margin recovers toward the full-year 8% to 10% target.
- SUSS MicroTec risk: Semiconductor-equipment orders can be lumpy. A strong order book is constructive, but investors should monitor customer project timing, AI-related demand durability, and any signs of order delays.
- Portfolio construction: The next addition should ideally reduce concentration while preserving EU exchange discipline. A third holding from a different sector, such as healthcare, industrial automation, energy infrastructure, or consumer defensives, would improve balance.
Close Decision
No positions should be closed this week. Both holdings are still within the protected minimum holding period, neither has suffered a thesis break, and both are currently positive on stored performance. Arcadis continues to show healthy order intake and backlog support, while SUSS MicroTec’s record order intake keeps the semiconductor-equipment thesis intact despite near-term margin and revenue-timing risks.
The correct portfolio action is to hold both positions, monitor execution, and look for a future opportunity to broaden the portfolio without diluting its European focus.
Risk disclaimer: This article is for informational and portfolio-review purposes only and is not financial advice. Stocks can decline in value, concentrated portfolios can be volatile, and investors should conduct their own research or consult a qualified financial adviser before making investment decisions.